.jpg)
1 hour ago
3
Article content
BROSSARD, Quebec, March 05, 2026 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (AI) techniques, announces that it intends to amend the terms of an aggregate amount of $510,000 of unsecured convertible debentures (each, a Debenture) issued as part of a non-brokered private placement of units initially announced on March 1, 2022, and subsequently amended on March 1, 2025 (pleaser refer to the press release dated February 28, 2025). The amendments are as follows:
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
- The amended maturity date set for March 1, 2026, as announced in the press release dated February 28, 2025, is extended to March 1, 2027,
- The conversion price of the Debentures is amended from $0.38 to $0.32, and
- The amended yearly interest rate of 10%, as announced in the press release dated February 28, 2025, remains in effect for the extended period from March 1, 2026 to March 1, 2027.
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
All other provisions of the Debentures shall remain unchanged and fully in effect during the extended period.
Article content
One insider of the Corporation, Mr. André Larente, is the beneficial owner of 2 Debentures for a nominal aggregate value of $20,000. Mr. Larente is considered a “related party” of the Corporation within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The amendment to the Debentures is exempt from the valuation requirement and the minority approval requirement prescribed in MI 61-101, based on sections 5.5(a) and 5.7(1)(a), as the fair market value of the related party participation in the amendment to the Debentures does not exceed 25% of the Corporation’s current market capitalization. The board of directors of the Corporation has reviewed and approved the amendment to the Debentures to ensure that it was in the best interest of DIAGNOS and its shareholders.
Article content
Article content
The Corporation also announces that it intends to extend the exercise period of 8,333,333 stock warrants (each a “Warrant”) issued as part of a non-brokered private placement of units initially announced on September 20, 2024 and set to expire on March 20, 2026. The extended expiry date shall be September 5, 2026. All other provisions of the Warrants, such as the Warrants exercise price of $0.40 per common share, shall remain unchanged and fully in effect during the extended exercise period.
Article content
The amendments to the Debentures and Warrants remain subject to the TSX Venture Exchange (the “Exchange”) acceptance as well as execution of formal documentation. The Corporation will issue a follow up press release solely in the case where the Exchange rejects any of the amendments.
Article content
All monies quoted in this press release shall be stated and paid in lawful money of Canada.
Article content
About DIAGNOS
Article content
DIAGNOS is a publicly traded Canadian corporation with a mission of developing software tools for the early detection of critical health issues through the use of Artificial Intelligence.
English (US)